![]() ![]() Sacubitril/valsartan is to be used in place of an ACEI or angiotensin II receptor blocker (ARB) and conjunction with other standard heart-failure treatments (beta-blocker, aldosterone antagonist). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class II, III, or IV. Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI).
0 Comments
Leave a Reply. |